Home Synthesis, radiolabeling and quality control of 111In-DOTA-bevacizumab for radioimmunoscintigraphy of VEGF receptors
Article
Licensed
Unlicensed Requires Authentication

Synthesis, radiolabeling and quality control of 111In-DOTA-bevacizumab for radioimmunoscintigraphy of VEGF receptors

  • A. Khorami-Moghadam , A. R. Jalilian EMAIL logo , K. Yavari , B. Alirezapour , M. Mazidi and M. Mirzaii
Published/Copyright: September 7, 2013

Summary

In this study, bevacizumab was successively labeled with 111In-InCl3 after conjugation with DOTA-NHS-ester followed by molecular filtration and determination of the average number ofDOTAconjugated per mAb (6 : 1) by spectrophotometric method. Radiochemical purity (> 97%, measured by ITLC and HPLC), integrity of protein after radiolabeling (gel electrophoresis) and stability of 111In-DOTA-Bevacizumab (in final formulation, human serum, liver/kidney homogenates) were determined in 24-72 h as well as biodistribution studies in wild-type rats and human colon cancer (SW-480) bearing mice. The accumulation of the radiolabeled antibody was consistent with the former reported Bevacizumab conjugates. Significant tumor uptake (8%) was observed at 72 h p.i. Tumor/muscle uptake ratios were 2.6 (24 h), 9.74 (48 h) and 25 (72 h). 111In- DOTA-Bevacizumab was prepared as a SPECT molecular imaging agent for diagnosis and follow-up of vascular endothelial growth factor A (VEGF-A) expression in oncology.

Published Online: 2013-09-07
Published in Print: 2013-09

© 2013 Oldenbourg Wissenschaftsverlag GmbH, Rosenheimer Str. 145, 81671 München

Downloaded on 28.11.2025 from https://www.degruyterbrill.com/document/doi/10.1524/ract.2013.2053/html?lang=en
Scroll to top button